BERMUDA-BUSINESS
17.1.2023 22:27:35 CET | Business Wire | Press release
The second annual Bermuda Risk Summit, presented by the Bermuda Business Development Agency (BDA), in partnership with the Association of Bermuda Insurers and Reinsurers (ABIR) and EY, will begin on March 6 with a keynote conversation with Bermuda’s Premier, The Hon. David Burt, JP, MP, followed by a group CEO panel.
Sophie Roberts, Head of The Insurer TV, will moderate the opening panel featuring Peter Bell, CEO & Managing Director, Everest Re, Stephen Catlin, Executive Chairman, Convex (Past Chair & Deputy Chair ABIR), Christopher Schaper, CEO, AIG Re (ABIR Deputy Chair), and Megan Thomas, CEO, Hamilton Re.
David Hart, CEO, BDA said, “The BDA is so pleased to be able to once again present this flagship event, which showcases the entire breadth and depth of the world’s risk capital. The Bermuda Risk Summit creates both long-term business development growth potential, in terms of deal making opportunities around the event in front of an extremely important June 1 renewal season, as well as, the immediate economic impacts of attracting business travelers to Bermuda that week.”
The immediate economic impact of last year’s event, which had 350 delegates (80 from overseas), including lodging, transportation, food and beverage, retail, and recreation, was estimated at over one million dollars, and supported around 200 jobs. This figure does not include the additional visitors who flew to Bermuda for business meetings around the event. The BDA anticipates an even stronger attendance level this year, as we continue to assist with building out Bermuda’s globally significant risk and insurance sector and showcasing Bermuda’s strengths.
Potential registrants are strongly encouraged to act soon to receive the early bird registration price, of $395, ending next Friday, 27 January. Included in the early bird price are keynote breakfasts, networking breaks and lunches at Hamilton Princess Hotel, an evening seaside soiree at the Hamilton Beach Club and an island lunch cruise. Visit our event webpage to register.
Overseas guests should also act before Friday, February 3 to secure special hotel room rates. After February 3, hotel room prices will increase significantly, or be completely sold out, due to limited availability. To book your room please call 1-441-295-3000 or the Global Reservations Centre on 1-800441-1414. Alternatively, click here to reserve your room online. Please use booking code: ‘Bermuda Risk’ to take advantage of the preferred rate.
In terms of sponsorships, the BDA is pleased to announce that Hyperexponential have come on board as a diamond sponsor, SS&C is a gold sponsor, AM Best and Kirkland & Ellis are silver sponsors, Demotech is WIFI sponsor, and The Insurer is our official media partner. Other sponsorship opportunities are still available. Please e-mail bermudarisk@bda.bm if you wish to participate.
The overall theme of the 2023 Bermuda Risk Summit, being held from March 6-8, is ‘Innovation, Sustainability and Collaboration.
Speakers confirmed to date include Suzanne Williams Charles, Director of Policy and Regulation, ABIR will moderate a panel of international regulators featuring Chlora Lindley-Myers, President, National Association of Insurance Commissioners and Gerald Gakundi, Director, Supervision (Insurance), Bermuda Monetary Authority.
Craig Redcliffe, Partner, EY will moderate an ‘Evolution of Partner Capital’ panel featuring Jasmine Desilva, SVP ILS, Artex Capital Solutions, Julia Henderson, Chief Commercial Officer, Vesttoo, and Sylvie Werther, Director of Operations/Reinsurance, Nephila Capital.
Joseph Petrelli, President, Demotech and Todd Kozikowski, President, 44North, LLC, will present their findings on Florida’s disparate litigation levels.
A panel discussing investor’s experiences of Bermuda will feature, Scott Frederick, Managing Partner, Sands Capital Ventures, Adrian Jones, Managing Director, Re/Insurance and Partner, HSCM Ventures, and Armin Rothauser, Senior Partner, Castlelake Investments.
Peter Giacone, Global Head of Insurance, KBRA, Stefan Holzberger, Chief Rating Officer, AM Best, and Joseph Petrelli, President, Demotech will speak on a panel entitled ‘Global Financing Conditions - A Rating Agency Discussion.’
Kerr Kennedy, Associate Partner, EY, will moderate Yosha Delong, Global Head of Cyber, Mosaic Insurance, Noel Pearman, SVP, Cyber Product Line Leader, AXA XL, Sebastien Plummer, Cyber Specialist Broker, Gallagher Re, and Edouard Von Heberstein, CEO Spectra who will explore the future of cyber reinsurance.
Saadia Savory, Vice President, Excess Casualty, Aspen, and Shannon Totten, SVP, Casualty Insurance Practice Leader Bermuda, Sompo International, will discuss Bermuda’s vibrant casualty lines of business.
Chris Hayward, Chief Underwriting Officer, MS Amlin Reinsurance, Mark Wheeler, Co-Chief Executive Officer & Director, Mosiac and Kostya Zolotusky, CEO, Itasca Re will explore diverse specialty lines of business.
And last but certainly not least, founder, chairman and CEO of SS&C, William C. Stone, will speak about innovative technology with Alex Huang, Chief Risk Officer, Sun Life International.
CONNECTING BUSINESS
The BDA encourages direct investment and helps companies start up, re-locate, or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business in Bermuda smooth and beneficial.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230117006105/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
